The HVTN 503/Phambili study: Efficacy is always the issue

The Lancet Infectious Diseases

Volumn 11, Issue 7, 2011, Pages 490-491

  Dhesi, Zaneeta ^a   Stebbing, Justin ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

CLADISTICS; CROSS REACTION; DRUG EFFICACY; EPIDEMIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; LETTER; PRIORITY JOURNAL; SOUTH AFRICA; VACCINATION; VIRUS LOAD;

AIDS VACCINES; CLINICAL TRIALS AS TOPIC; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; SOUTH AFRICA;

EID: 79959291547     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(11)70103-7     Document Type: Letter

References (12)

1. Heeney J, Dalgleish A, Weiss R Origins of HIV and the evolution of resistance to AIDS. Science 2006, 313:462-466.
2. McCutchan FE Understanding the genetic diversity of HIV-1. AIDS 2000, 14(suppl 3):S31-S44.
3. Gray GE, Allen M, Moodie Z, et al. Safety and efficacy of the HVTN 503/Phambili Study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis 2011, published online May 12. 10.1016/S1473-3099(11)70098-6.
4. Santra S, Seaman MS, Xu L, et al. Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J Virol 2005, 79:6516-6522.
5. Priddy FH, Brown D, Kublin J, et al. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis 2008, 46:1769-1781.
6. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008, 372:1881-1893.
7. Gupta R, Towers G A tail of Tetherin: how pandemic HIV-1 conquered the world. Cell Host Microbe 2009, 6:393-395.
8. Coplan PM, Gupta SB, Dubey SA, et al. Cross-reactivity of anti-HIV-1 T cell immune responses among the major HIV-1 clades in HIV-1-positive individuals from 4 continents. J Infect Dis 2005, 191:1427-1434.
9. McElrath MJ, De Rosa SC, Moodie Z, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008, 372:1894-1905.
10. Ramjee G, Williams B, Gouws E, Van Dyck E, De Deken B, Karim SA The impact of incident and prevalent herpes simplex virus-2 infection on the incidence of HIV-1 infection among commercial sex workers in South Africa. J Aquir Immune Defic Syndr 2005, 39:333-339.
11. McCormack S, Ramjee G, Kamali A, et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet 2010, 376:1329-1337.
12. Dalgleish A, Stebbing J HIV-1 step study. Lancet 2009, 373:805.